My Watchlist

Top Indices

Nasdaq Composite

SPX

My Portfolio

Novo Nordisk A/S Common Stock (NY:NVO)

59.64 UNCHANGED

Streaming Delayed Price Updated: 7:00 PM EST, Jan 13, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Novo Nordisk A/S Common Stock

< Previous 1 2 3 4 5 6 7 8 9

...

99 100 Next >

Eli Lilly Stock Rallies as Ventyx Deal Calms Wegovy Concerns ↗

January 13, 2026

Via MarketBeat

The Great Recalibration: Why 2026 Could Be Healthcare’s Year to Rebound

January 13, 2026

For the past two years, the U.S. healthcare sector has been the forgotten stepchild of the equity markets. As the S&P 500 (SPX) surged on the back of an artificial intelligence gold rush and a...

Via MarketMinute

January 13, 2026

Via Stocktwits

Amgen at the Crossroads: MariTide, Market Volatility, and the Quest for Obesity Dominance

January 13, 2026

Date: January 13, 2026 Introduction Amgen Inc. (NASDAQ: AMGN) finds itself at a historic crossroads. Long regarded as the "blue-chip" anchor of the biotechnology sector, the Thousand Oaks-based giant...

Via PredictStreet

Topics Economy Intellectual Property

Why Is HIMS Stock Slipping Premarket Today? ↗

January 12, 2026

Via Stocktwits

Eli Lilly vs Novo Nordisk: Which Company Will Dominate the Weight Loss Drug Market in 2026? ↗

January 13, 2026

Both companies now aim to win in the oral weight loss drug market.

Via The Motley Fool

Can Novo Nordisk Unseat Eli Lilly as the Weight Loss Drug Leader in 2026? ↗

January 13, 2026

The gap may be too hard to close in the next 12 months.

Via The Motley Fool

Why Tempus AI Stock Rose Today ↗

January 12, 2026

The data provider's artificial intelligence-driven solutions are accelerating drug discovery.

Via The Motley Fool

Topics Artificial Intelligence

Beyond the Protein: How AlphaFold 3 Redefined the Blueprint of Life and Accelerated the Drug Discovery Revolution

January 12, 2026

In the two years since its unveiling, AlphaFold 3 (AF3) has fundamentally transformed the landscape of biological research, moving the industry from simple protein folding to a comprehensive "all-atom"...

Via TokenRing AI

Topics Artificial Intelligence

Anthropic Launches “Claude for Healthcare”: A Paradigm Shift in Medical AI Integration and HIPAA Security

January 12, 2026

On January 11, 2026, Anthropic officially unveiled Claude for Healthcare, a specialized suite of artificial intelligence tools designed to bridge the gap between frontier large language models and the...

Via TokenRing AI

Topics Artificial Intelligence

From Silicon to Syringes: Nvidia’s AI Dominance Solidified Through Landmark Eli Lilly Alliance

January 12, 2026

In a move that signals the definitive convergence of high-performance computing and biotechnology, NVIDIA Corporation (NASDAQ: NVDA) and Eli Lilly and Company (NYSE: LLY) announced a massive $1 billion...

Via MarketMinute

Topics Artificial Intelligence Economy Intellectual Property

The Convergence of Silicon and Science: Eli Lilly and Nvidia Unveil $1 Billion AI Co-Innovation Lab at JPM26

January 12, 2026

In a move that signals the definitive arrival of the "AI-first" era for the pharmaceutical industry, Eli Lilly and Company (NYSE:LLY) and NVIDIA Corporation (NASDAQ:NVDA) announced a massive expansion...

Via MarketMinute

Topics Artificial Intelligence

An Investor's Guide to 2026 ↗

January 12, 2026

What does the new year bring to investors?

Via The Motley Fool

Topics Artificial Intelligence Economy

Stocks to Love in 2026 ↗

January 11, 2026

Are you looking for investment opportunities in 2026?

Via The Motley Fool

Topics ETFs Initial Public Offering

This ETF Is Proof That the Healthcare Rebound Is Real ↗

January 11, 2026

Via MarketBeat

Topics ETFs

This Healthcare Stock Could Be One of the Best Companies to Own in 2026 ↗

January 11, 2026

It has strong momentum thanks to its current portfolio and several catalysts on the horizon.

Via The Motley Fool

Eli Lilly Solidifies Immunology Dominance with $1.2 Billion Acquisition of Ventyx Biosciences

January 09, 2026

In a move that underscores the tightening intersection between metabolic health and systemic inflammation, Eli Lilly and Company (NYSE: LLY) officially announced on January 7, 2026, its definitive...

Via MarketMinute

The Great Pricing Pivot: Novo Nordisk Launches Wegovy Pill in Bid to Reclaim US Market Dominance

January 09, 2026

As the first full week of 2026 unfolds, the pharmaceutical landscape is witnessing a seismic shift led by the Danish healthcare giant Novo Nordisk (NYSE: NVO). On January 5, 2026, the company...

Via MarketMinute

Topics Economy

The Trillion-Dollar Pharmacist: A 2026 Deep Dive into Eli Lilly (LLY)

January 09, 2026

As of January 9, 2026, Eli Lilly and Company (NYSE:LLY) has transitioned from a stalwart of the American pharmaceutical industry to a global financial phenomenon. Having recently crossed the historic...

Via PredictStreet

Topics Earnings Economy Intellectual Property

Nvidia’s $5 Trillion Peak Sparks Massive Nasdaq Retreat as Investors Pivot to Value

January 08, 2026

The tech-heavy Nasdaq Composite faced a stark reversal on January 8, 2026, as a wave of profit-taking in high-flying artificial intelligence stocks, led by Nvidia (NASDAQ: NVDA), dragged the index...

Via MarketMinute

Topics Artificial Intelligence Economy Stocks

3 of the Best Stocks Under $100 to Buy in 2026 ↗

January 08, 2026

These stocks are big names in their respective industries, and their prices make them look like bargain buys.

Via The Motley Fool

The 2026 Pharma M&A Outlook: Obesity, HIV, and the Biotech Renaissance

January 07, 2026

As the pharmaceutical industry rings in 2026, the landscape of healthcare investment has shifted from cautious recovery to a full-scale acquisition frenzy. Driven by a looming "super-cliff" of patent...

Via MarketMinute

Topics Artificial Intelligence Economy Intellectual Property

The Trillion-Dollar Treatment: Eli Lilly Solidifies Dominance as Obesity Drug Boom Enters New Era

January 07, 2026

As the calendar turns to early 2026, the global pharmaceutical landscape is being redefined by a single, seismic force: the metabolic health revolution. At the epicenter of this transformation stands...

Via MarketMinute

Topics Economy

Warning: This Skyrocketing Stock Has a Hidden Risk ↗

January 06, 2026

Novo Nordisk's new GLP-1 pill highlights the risk that Eli Lilly faces, as investors reward it for being at the forefront of the weight loss market.

Via The Motley Fool

Should Investors Be Concerned About This Pharmaceutical Giant's Latest Clinical Trial? ↗

January 06, 2026

Novo Nordisk has some good GLP-1 news, but is the company's failed Alzheimer's trial a long-term problem?

Via The Motley Fool

Topics Intellectual Property

The Trillion-Dollar Pivot: Eli Lilly Unleashes Volume-Led Strategy to Cement Obesity Market Dominance in 2026

January 06, 2026

As of January 6, 2026, the landscape of the pharmaceutical industry has been fundamentally reshaped by Eli Lilly and Company (NYSE:LLY), which recently became the first healthcare entity to surpass a...

Via MarketMinute

Topics Economy

The Great Rebalancing: Why Healthcare is Leading the Market Charge in 2026

January 06, 2026

As the first week of 2026 draws to a close, a distinct shift in market leadership has become the defining story for Wall Street. After a multi-year period where technology and artificial intelligence...

Via MarketMinute

Topics Artificial Intelligence Economy Government

The Great 2026 Pivot: Tech and Healthcare Surge as Broader Market Rally Hits a Wall

January 06, 2026

As the first week of 2026 comes to a close, the financial markets are undergoing a significant structural shift. The broad-based "rising tide" that lifted almost all sectors throughout 2025 has begun...

Via MarketMinute

Topics Artificial Intelligence Economy Stocks

Should You Buy Eli Lilly Before It Reaches $1 Trillion in Market Value? ↗

January 06, 2026

Eli Lilly offers investors safety and growth.

Via The Motley Fool

Eli Lilly Heads Toward A Defining 2026 — Can It Stay Ahead Of Novo Nordisk In The GLP-1 Showdown? ↗

January 06, 2026

Several clinical readouts and regulatory decisions are scheduled for Eli Lilly in 2026.

Via Stocktwits

< Previous 1 2 3 4 5 6 7 8 9

...

99 100 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.